
Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
2023-01-12
0:00
15:01
Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ.
Related Content:
Fler avsnitt från "JAMA Author Interviews"
Missa inte ett avsnitt av “JAMA Author Interviews” och prenumerera på det i GetPodcast-appen.